Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6209 with endocrine therapy and/or HRS-9813 in HR-positive/HER2-negative breast cancer or HRS-9813 in advanced solid tumors
CTR20242896Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HRS-6209 and HRS-9813 in breast cancer and Nonhematologic neoplasms (2 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Aug 2024; status: active.
02
Drugs
HRS-6209HRS-9813
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242896.